Vivani Medical, Inc. Announces Closing of Common Stock Offering
Rhea-AI Summary
Vivani Medical (Nasdaq: VANI) closed a registered direct offering and a concurrent private placement on January 27, 2026, selling a combined 3,040,551 shares at $1.48 per share for gross proceeds of approximately $4.5 million before fees and expenses. The private placement included 1,351,351 shares purchased by Chairman Gregg Williams. Proceeds are intended to fund ongoing research and clinical development of NanoPortal implants, plus working capital and general corporate purposes. ThinkEquity acted as sole placement agent for the registered offering.
Positive
- Gross proceeds of approximately $4.5 million
- Insider participation: 1,351,351 shares purchased by chairman Gregg Williams
- Proceeds earmarked for research and clinical development
Negative
- Issued a total of 3,040,551 shares, increasing share count
- Offering priced at-the-market, which can add near-term selling pressure
News Market Reaction – VANI
In the Jan 28 session, VANI gained 7.97%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.0% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 3.6x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Oct 28 | Offering closing | Negative | +3.1% | Closed registered direct and private placement totaling about $15.7M gross. |
| Oct 26 | Offering pricing | Negative | +0.0% | Priced best-efforts registered direct and concurrent private placement at $1.62. |
| Mar 01 | Offering pricing | Negative | -26.8% | Announced $15.0M registered direct offering of common stock and warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past equity offerings have produced mixed reactions, from a sharp selloff to modest gains or flat trading, indicating no consistent directional pattern to financing news.
This announcement adds another equity financing to Vivani’s recent capital-raising history. Prior offerings on Oct 26–28, 2025 involved registered direct and concurrent private placements at $1.62, generating about $15.7 million gross and leading to mixed share reactions (from flat to a 3.09% gain). A Mar 1, 2024 financing saw a -26.78% move. Today’s smaller raise continues the pattern of using common stock offerings to fund development programs.
Key Terms
registered direct offering financial
private placement financial
prospectus supplement regulatory
at-the-market financial
GLP-1 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALAMEDA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of
The registered offering and the private placement were priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC.
The Company intends to use the net proceeds from the registered offering and private placement to fund ongoing research and clinical development of the Company’s product candidates, as well as for working capital and general corporate purposes.
ThinkEquity acted as sole placement agent for the registered direct offering.
The securities in the registered direct offering were offered and issued pursuant to a shelf registration statement on Form S-3 (File No. 333-278869), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 22, 2024 and declared effective on May 3, 2024. The offering was made only by means of a written prospectus. A final prospectus supplement and accompanying prospectus describing the terms of the offering was filed with the SEC and is available on its website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Vivani Medical, Inc:
Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately
Forward-Looking Statements:
This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that are used in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential thereof, the planned development thereof, and its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays; and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 31, 2025, as updated by the Company’s subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.
For Investor Relations Inquiries:
Company Contact:
Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462
Investor Relations Contact:
Jami Taylor
Investor Relations Advisor
investors@vivani.com
(415) 506-8462
Media Contact:
Sean Leous
ICR Healthcare
Sean.Leous@ICRHealthcare.com
(646) 866-4012
